Publicado may 29, 2013



PLUMX
Almetrics
 
Dimensions
 

Google Scholar
 
Search GoogleScholar


Iván Mauricio Alvarado Arteaga

##plugins.themes.bootstrap3.article.details##

Resumen

Recientes avances en el entendimiento de la fisiología de la coagulación han llevado al desarrollo de nuevas teorías, más congruentes y mejor correlacionadas con las alteraciones clínicas. El presente texto discute la evidencia reciente molecular y celular, la fusiona en un modelo conceptual sencillo y unificado, y lo aplica al entendimiento de las diversas alteraciones y fármacos que afectan la hemostasia en el periodo perioperatorio.

Keywords

hemostasia, coagulación, fisiología, cuidado perioperatorio, Hemostasis, blood coagulation, physiology, perioperative care,

References
1. Gale AJ. Continuing education course #2: current understanding of hemostasis. Toxicol Pathol. 2011 Jan;39(1):273-80. Epub 2010 Nov 30.
2. Adams RL, Bird RJ. Review article: Coagulation cascade and therapeutics update: relevance to nephrology. Part 1: Overview of coagulation, thrombophilias and history of anticoagulants. Nephrology (Carlton). 2009 Aug;14(5):462-70.
3. Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg. 2009 May;108 (5):1433-46.
4. Smith SA. The cell-based model of coagulation. J Vet Emerg Crit Care (San Antonio). 2009 Feb;19(1):3-10.
5. Hoffman M, Monroe DM. Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin North Am. 2007 Feb;21(1):1-11.
6. O’Connor SD, Taylor AJ, Williams EC, Winter TC. Coagulation concepts update. AJR Am J Roentgenol. 2009 Dec;193(6):1656-64.
7. Eyre L, Gamlin F. Haemostasis, blood platelets and coagulation. Anaesth Intensive Care Med. 2010;11(6):244-246.
8. Kriz N, Rinder CS, Rinder HM. Physiology of hemostasis: with relevance to current and future laboratory testing. Clin Lab Med. 2009 Jun;29(2):159-74.
9. Davie EW, Ratnoff SI. Waterfall sequence for intrinsic blood clotting. Science. 1964;145:1310-2.
10. Davidson CJ, Tuddenham EG, McVey JH. 450 million years of hemostasis. J Thromb Haemost. 2003;1:1487-94.
11. Osterud B, Rappaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad. Sci. U.S.A. 1977;74:5260-4.
12. Gailani D, Renne T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease? J Thromb Haemost. 2007;5(6):1106-12.
13. Key NS, Geng J, Bach RR. Tissue factor: from Morawitz to microparticles. Trans Am Clin Climatol Assoc. 2007;118:165-73.
14. Nemerson Y. The tissue factor pathway of blood coagulation. Semin Hematol. 1992;29:170-6.
15. Goodeve AC, Rosén S, Verbruggen B. Haemophilia A and von Willebrand‘s disease. Haemophilia. 2010 Jul;16 Suppl 5:79-84.
16. Lenting PJ, Pegon JN, Christophe OD, Denis CV. Factor VIII and von Willebrand factor--too sweet for their own good. Haemophilia. 2010 Jul;16 Suppl 5:194-9.
17. Coughlin SR. Protease-activated receptors and platelet function. Thromb Haemost 1999;82:353-6.
18. Vretenbrant K, Ramström S, Bjerke M, Lindahl TL. Platelet activation via PAR4 is involved in the initiation of thrombin generation and in clot elasticity development. Thromb Haemost. 2007 Mar;97(3):417-24.
19. Kempton CL, Hoffman M, Roberts HR et al. Platelet heterogeneity: Variation in coagulation complexes on platelet subpopulations. Arterioscler Thromb Vasc Biol. 2005;25(4):861-6.
20. Yamaji-Hasegawa A, Tsujimoto M. Asymmetric distribution of phospholipids in biomembranes. Biol Pharm Bull. 2006;29(8):1547-53.
21. Zwaal RF, Comfurius P, Bevers EM. Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci. 2005;62(9):971-88.
22. Alberio L, Safa O, Clemetson KJ, et al. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood. 2000;95:1694-702.
23. Monroe DM, Roberts HR, Hoffman M. Platelet procoagulant complex assembly in a tissue factor-initiated system. Br J Haematol. 1994;88:364-71.
24. Lee A, Crowther M. Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. J Thromb Thrombolysis. 2011 Apr;31(3):249-58.
25. Blomback B, Bark N. Fibrinopeptides and fibrin gel structure. Biophys Chem. 2004;112(2-3):147-51.
26. Lauricella AM. Fibrin network variability. Acta Bioquím Clín Latinoam. 2007;41(1).
27. Hornyak TJ, Shafer JA. Interactions of factor XIII with fibrin as substrate and cofactor. Biochemistry. 1992;31:423-9.
28. Peerschke EI, Zucker MB, Grant RA, Egan JJ, Johnson MM. Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood. 1980 May;55(5):841-7.
29. Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther. 2008 Apr;118(1):18-35. Epub 2008 Jan 26.
30. Kim S, Kunapuli SP. P2Y12 receptor in platelet activation. Platelets. 2011; 22(1):54-8. Review. PubMed PMID: 21231822.
31. Robert T. Dorsam, Satya P, et al. Central role of the P2Y12 receptor in platelet activation. Clin Invest. 2004;113(3):340-45.
32. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombinactivable fibrinolysis inhibitor. J Biol Chem. 1995;270:14477-84.
33. Ott I, Miyagi Y, Miyazaki K, et al. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 2000;20:874-82.
34. Shimada K, Kobayashi M, Kimura S, Nishinaga M, Takeuchi K, Ozawa T. Anticoagulant heparin-like glycosaminoglycans on endothelial cell surface. Jpn Circ J. 1991 Oct;55(10):1016-21.
35. Owen WG, Esmon CT. Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. J Biol Chem. 1981 Jun 10;256(11):5532-5. PubMed PMID: 6894592.
36. Jin RC, Voetsch B, Loscalzo J. Endogenous mechanisms of inhibition of platelet function. Microcirculation. 2005 Apr-May;12(3):247-58.
37. Szymanski LM, Pate RR, Durstine JL. Effects of maximal exercise and venous occlusion on fibrinolytic activity in physically active and inactive men. J Appl Physiol. 1994;77:2305-10.
38. Anglés-Cano E. Overview on fibrinolysis: plasminogen activation pathways on fibrin and cell surfaces. Chem Phys Lipids. 1994 Jan;67-68:353-62.
39. Kitchens CS. To bleed or not to bleed? Is that the question for the PTT? J Thromb Haemost. 2005 Dec;3(12):2607-11. Epub 2005 Sep 9.
40. Shaw PH, Reynolds S, Gunawardena S, et al. The prevalence of bleeding disorders among healthy pediatric patients with abnormal preprocedural coagulation studies. J Pediatr Hematol Oncol. 2008;30:135-41.
41. Kozek-Langenecker SA. Perioperative coagulation monitoring. Review. Best Pract Res Clin Anaesthesiol. 2010 Mar;24(1):27-40.
42. Innerhofer P, Kienast J. Principles of perioperative coagulopathy. Best Pract Res Clin Anaesthesiol. 2010 Mar;24(1):1-14.
43. Rajagopalan S, Mascha E, Na J, Sessler DI. The effects of mild perioperative hypothermia on blood loss and transfusion requirement. Anesthesiology. 2008 Jan;108(1):71-7.
44. Peyvandi F, Cattaneo M, Inbal A, De Moerloose P, Spreafico M. Rare bleeding disorders. Haemophilia. 2008 Jul;14 Suppl 3:202-10.
45. Martlew VJ. Peri-operative management of patients with coagulation disorders. Br J Anaesth. 2000 Sep;85(3):446-55.
46. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999 Jun;57(6):1005-32.
47. Alvarado IM. Tendencias actuales en el manejo preoperatorio de pacientes anticoagulados con warfarina. Rev Colomb Anestesiol. 2012;40(1):52-9.
48. Dumont B, Faille D, Ajzenberg N. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future]. Med Sci (Paris). 2011 May;27(5):493-500. Epub 2011 May 25.
49. Sun JC, Whitlock R, Cheng J, , et al. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. Eur Heart J. 2008;29:1057-71.
50. Harder S, Klinkhardt U, Alvarez JM. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2004;43(14):963-81.
51. Fleisher LA, Beckman JA, Brown KA, Calkins H, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Anesth Analg. 2008 Mar;106(3):685-712.
52. Savonitto S, D‘Urbano M, Caracciolo M, Barlocco F, et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of ‚bridging‘ antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth. 2010 Mar;104(3):285-91.
Cómo citar
Alvarado Arteaga, I. M. (2013). Fisiología de la coagulación: nuevos conceptos aplicados al cuidado perioperatorio. Universitas Medica, 54(3), 338–352. https://doi.org/10.11144/Javeriana.umed54-3.fcnc
Sección
Artículos de revisión